• An Early-Stage THx, Dx & Device Focus:

    Welcome to the site formerly known as [Colorado] Life Science Deal Flow. This new version looks at the biopharma world primarily from an early-stage financing perspective. Be certain to visit our companion site, a FREE Venture Capital dBase, OnBioVC.com, and subscribe by email or RSS.
  • SEARCH the Life Science Deal Flow ARCHIVE

  • business strategy life science

NOTE: Apologies for the delayed post release. 22″ of October snow yielded a slow start to the day…
Waltham, MA-based Synageva Biopharma (formerly AviGenics) is focused on novel, next-generation and follow-on protein therapeutics that leverage their Synageva Expression Platform (SEP™). SEP™ is an integrated platform of proprietary vectors and protein production, processing and purification systems [...]

GlobeImmune, Inc. closed a $41.2MM Series C financing. The round was led by Wexford Capital, other participants include Celgene (NASDAQ: CELG), Mellon Family Investment Company, Richard King Mellon Foundation, Eminent Venture Capital Corp., Boston Life Science Venture, and WRF Capital. Previous investors who participated in the round include HealthCare Ventures, Morgenthaler Ventures, Sequel Venture Partners, [...]

  

to top of page...


 
  • The Latest LSDF Activity

    September 2010
    M T W T F S S
    « Aug    
     12345
    6789101112
    13141516171819
    20212223242526
    27282930  
  • Search the LSDF Archive

  • Your Advert Can Go Here!

    Find out how, email: arubenstein@rnaventures.com